Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD)

11 Nov 2020 10:58

RNS Number : 9834E
Horizon Discovery Group plc
11 November 2020
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Horizon Discovery Group plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Horizon Discovery Group plc

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

10 November 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

Nil

Nil

(2) Cash-settled derivatives:

 

Nil

Nil

Nil

Nil

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

Nil

Nil

Nil

 

TOTAL:

Nil

Nil

Nil

Nil

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

a) Holdings of ordinary shares of 1p each in Horizon Discovery Group plc by directors and their close relatives

 

Name

No. of ordinary shares held

Percentage of issued share capital

Terry Pizzie

42,285

0.03%

Jayesh Pankhania

90,768

0.06%

Ian Gilham

145,592

0.09%

Grahame Cook

142,250

0.09%

Susan Searle

90,000

0.06%

Vishal Gulati

14,100

0.01%

 

b) The Directors hold the following number of options to acquire ordinary shares in the Company:

 

Name

No. of share options held

Ian Gilham

143,250

Terry Pizzie

1,245,818

Jayesh Pankhania

666,550

Dr Siddhartha Kadia

150,000

 

 

1) Ian Gilham

 

EMI Scheme

 

Options granted

Grant Price

Grant Date

Vest Date

Expiry Date

57,300

£0.6774

18-Oct-2013

18-Oct-2017

18-Oct-2023

85,950

£0.8726

18-Mar-2014

18-Mar-2017

18-Mar-2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2) Terry Pizzie

 

Long Term Incentive Plan

 

Options granted

Grant Price

Grant Date

Vest quant 1

Vest Date 1

Vest quant 2

Vest date 2

Vest quant 3

Vest date 3

Expiry Date

60,185

£1.62

07-Apr-2017

60,185

07-Apr-2020

07-Apr-2027

7,812

£0.01

01-Nov-2017

2,604

01-Nov-2018

2,604

01-Nov-2019

2,604

01-Nov-2020

01-Nov-2027

15,031

£1.57

10-May-2018

5,010

10-May-2019

5,010

10-May-2020

5,011

10-May-2021

10-May-2028

41,401

£0.01

10-May-2018

13,800

10-May-2020

13,800

10-May-2021

13,801

10-May-2022

10-May-2028

3,199

£2.00

09-Nov-2018

799

09-Nov-2021

800

09-Nov-2022

1,600

09-Nov-2023

09-Nov-2028

321,801

£2.00

09-Nov-2018

80,450

09-Nov-2021

80,450

09-Nov-2022

160,901

09-Nov-2023

09-Nov-2028

624,594

£1.64

26-Feb-2020

624,594

26-Feb-2023

26-Feb-2030

85,863

£0.01

26-Feb-2020

42,932

26-Feb-2022

42,931

26-Feb-2023

26-Feb-2030

70,730

£0.01

15-Mar-2019

35,365

15-Mar-2021

35,365

15-Mar-2022

15-Mar-2029

 

Sharesave

 

Options granted

Grant Price

Grant Date

Vest Date

Expiry Date

15,202

£1.184

05-Jul-2019

01-Sep-2022

01-Mar-2023

 

3) Jayesh Pankhania

 

Long Term Incentive Plan

 

Options granted

Grant Price

Grant Date

Vest quant 1

Vest Date 1

Vest quant 2

Vest date 2

Vest quant 3

Vest date 3

Expiry Date

17,167

£1.7475

06-Feb-2019

4,291

06-Feb-2022

4,292

06-Feb-2023

8,584

06-Feb-2024

06-Feb-2029

111,588

£1.7475

06-Feb-2019

27,897

06-Feb-2022

27,897

06-Feb-2023

55,794

06-Feb-2024

06-Feb-2029

45,064

£0.01

06-Feb-2019

15,021

06-Feb-2021

15,022

06-Feb-2022

15,021

06-Feb-2023

06-Feb-2029

419,817

£1.64

26-Feb-2020

419,817

26-Feb-2023

26-Feb-2030

57,712

£0.01

26-Feb-2020

28,856

26-Feb-2022

28,856

26-Feb-2023

26-Feb-2030

 

Sharesave

 

Options granted

Grant Price

Grant Date

Vest Date

Expiry Date

15,202

£1.184

05-Jul-2019

01-Sep-2022

01-Mar-2023

 

 

 

 

4) Dr Siddhartha Kadia

Long Term Incentive Plan

 

Options granted

Grant Price

Grant Date

Vest quant 1

Vest Date 1

Vest quant 2

Vest date 2

Vest quant 3

Vest date 3

Expiry Date

150,000

£1.03

18-Jun-2020

50,000

18-Jun-2021

50,000

18-Jun-2022

50,000

18-Jun-2023

18-Jun-2030

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

11 November 2020

Contact name:

Teifion Hill

Telephone number:

 01223 976000

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEFFWFSFESSEIF
Date   Source Headline
16th Jan 20177:00 amRNSHorizon broadens gene editing capabilities
13th Jan 20177:00 amRNSAdditional Listing
6th Jan 20171:24 pmRNSAdditional Listing
29th Dec 201610:28 amRNSHolding(s) in Company
15th Dec 20167:00 amRNSAdditional Listing
2nd Dec 201611:30 amRNSDirector/PDMR Shareholding
2nd Dec 201610:00 amRNSDirector Dealings
16th Nov 20167:00 amRNSHZD Enters Chinese Clinical Diagnostics Market
14th Nov 20167:00 amRNSAdditional Listing
9th Nov 20167:00 amRNSOEM Agreement with CareDx for Reference Standards
1st Nov 20167:00 amRNSProgress Update: Molecular Screening Platform
31st Oct 201612:36 pmRNSAdditional Listing
19th Oct 20167:00 amRNSLicensing Agreement: Biomanufacturing Cell Lines
10th Oct 20167:00 amRNSAdditional Listing
30th Sep 20163:25 pmRNSHolding(s) in Company
30th Sep 20167:00 amRNSAdditional Listing
23rd Sep 20161:46 pmRNSHolding(s) in Company
21st Sep 20165:28 pmRNSHolding(s) in Company
20th Sep 20167:00 amRNSInterim Results for Six Months Ended 30 June 2016
13th Sep 20169:04 amRNSHolding(s) in Company
13th Sep 20167:00 amRNSBiomanufacturing Cell Lines Licensed to CPI, NIBRT
12th Sep 201611:04 amRNSHolding(s) in Company
7th Sep 201612:19 pmRNSHolding(s) in Company
7th Sep 20167:02 amRNSNotice of Interim Results
7th Sep 20167:00 amRNSAdditional Listing
6th Sep 201612:31 pmRNSHolding(s) in Company
6th Sep 20167:00 amRNSCRISPR Collaboration with Fulcrum Therapeutics
1st Sep 20167:00 amRNSHZD and Ventana Sign Reference Standards Agreement
18th Aug 20167:00 amRNSAdditional Listing
16th Aug 20164:09 pmRNSHolding(s) in Company
3rd Aug 20163:26 pmRNSHolding(s) in Company
29th Jul 20163:31 pmRNSHolding(s) in Company
28th Jul 20167:00 amRNSHorizon Discovery Group Issue of Equity
26th Jul 201610:47 amRNSAdditional Listing
21st Jul 20169:11 amRNSAdditional Listing
13th Jul 20161:20 pmRNSHoldings in Company
7th Jul 20169:17 amRNSHoldings in Company
4th Jul 20164:33 pmRNSHoldings in Company
29th Jun 20164:01 pmRNSAdditional Listing
28th Jun 20167:00 amRNSAdditional Listing
24th Jun 201611:20 amRNSResult of AGM
9th Jun 20162:21 pmRNSGrant of Options
7th Jun 20165:19 pmRNSAnnual Report and Notice of Annual General Meeting
3rd Jun 20167:00 amRNSAdditional Listing
1st Jun 20167:00 amRNSReference Standards used in QIAGEN NGS System
12th May 20167:00 amRNSOEM Agreements with Market Leading NGS Company
11th May 20167:00 amRNSAdditional Listing
28th Apr 20167:45 amRNSAdditional Listing
26th Apr 20167:35 amRNSPreliminary Results for the Year Ended 31 Dec 2015
19th Apr 20167:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.